Streamlining Oncology Waystar Clearinghouse Workflows for Prior Authorization

Klivira's platform optimizes the complex demands of oncology prior authorization, integrating seamlessly with your existing oncology Waystar clearinghouse workflows to accelerate treatment initiation and improve revenue cycle efficiency.

Oncology care presents unique challenges for prior authorization, from high-cost biologics to frequent regimen changes. Revenue cycle directors and prior authorization coordinators require robust solutions that can manage this volume and complexity, ensuring timely access to critical therapies while maintaining financial integrity.

The Prior Authorization Burden in Oncology

Oncology prior authorizations are among the most intricate and high-volume in healthcare, driven by high-cost biologics, infusion therapies, and advanced imaging. The rapid pace of treatment innovation and frequent regimen adjustments mean a single patient may trigger dozens of PA events, requiring continuous vigilance from PA teams.

High-Volume Oncology PA Triggers

HCPCS J-codes for chemotherapy and biologic infusions, including immunotherapies and targeted therapies.
Advanced imaging for staging and surveillance, such as PET/CT and tumor-specific molecular imaging.
Radiation oncology procedures, including IMRT, IGRT, SBRT, and proton-beam therapy.
Genetic and molecular testing for treatment selection and risk stratification.
Specialty oral oncolytics and supportive care medications requiring pharmacy benefit PAs.

Optimizing Oncology PA Submissions with Waystar Clearinghouse

Leveraging a robust clearinghouse like Waystar is critical for efficient revenue cycle management in oncology. Klivira integrates with your EMR to automate the data collection and submission preparation for prior authorizations, then facilitates the electronic transmission of associated eligibility inquiries and PA requests (e.g., via X12 278) through clearinghouse channels, minimizing manual data entry and accelerating payer communication.

Navigating Documentation Requirements for Oncology Approvals

Oncology prior authorizations are heavily reliant on comprehensive clinical documentation, often guided by NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium. Klivira's platform is designed to prompt for specific data points at the point of order entry, ensuring all required elements—from pathology reports and molecular markers to prior-line treatment responses and performance status—are captured for submission.

Common Oncology PA Denial Vectors

Off-label use lacking NCCN Compendium support for the requested tumor type or line of therapy.
Step therapy requirements not met, necessitating failure or contraindication for a less costly alternative.
Documentation gaps, such as missing molecular marker results or insufficient rationale for regimen changes.
Site-of-service mismatches, where the requested setting (e.g., HOPD vs. home infusion) conflicts with payer policy.
NCD/LCD non-coverage for Medicare Advantage plans, requiring adherence to Original Medicare's rules.

Klivira's Strategic Approach to Oncology PA Automation

Klivira's platform tackles the unique operational constraints of oncology PA, including the urgency of treatment initiation and the need for regimen-level approvals. Our solution provides NCCN-compendium-aware policy logic, manages the complex medical-vs-pharmacy benefit routing, and tracks concurrent PA events across a patient's entire treatment course, offering a comprehensive view within your existing EMR and RCM ecosystem.

Addressing Medical vs. Pharmacy Benefit Oncology Drugs

The split between medical benefit (IV infusions) and pharmacy benefit (oral oncolytics) significantly impacts PA pathways. Klivira intelligently routes medical-benefit PA requests through the appropriate payer medical channels (often leveraging X12 278 via a clearinghouse like Waystar), while pharmacy-benefit requests are directed to the payer's PBM and ePA partners (e.g., CoverMyMeds, Surescripts), ensuring each drug category follows the correct submission protocol.

Frequently asked questions

How does Klivira handle the frequent regimen changes in oncology for PA?

Klivira's platform is designed for regimen-level PA workflows, not just single-drug approvals. It tracks and manages new PA cycles triggered by changes in treatment due to toxicity or progression, ensuring timely submission of updated documentation and preventing delays in critical care.

Can Klivira integrate with my EMR to pull oncology-specific documentation?

Yes, Klivira integrates with major EMRs using standards like SMART on FHIR to pull critical oncology documentation, including pathology reports, molecular marker results, and performance status scores, directly into the PA request. This minimizes manual data extraction and improves data accuracy.

How does Klivira support NCCN guideline adherence in oncology PA?

Klivira incorporates NCCN-compendium-aware policy logic to guide PA submissions. The system surfaces required documentation and rationale based on specific tumor types and regimens, helping ensure that requests align with established medical necessity criteria and reducing denials related to unsupported off-label use.

What is the role of a clearinghouse like Waystar in Klivira's oncology PA workflow?

While Klivira automates the clinical documentation and PA request generation, a clearinghouse like Waystar plays a crucial role in the electronic transmission of eligibility verification and X12 278 PA requests to payers. Klivira optimizes the data preparation, allowing Waystar to efficiently handle the secure, standardized communication with health plans.

How does Klivira manage the split between medical and pharmacy benefit oncology drugs?

Klivira intelligently identifies whether an oncology drug falls under the medical or pharmacy benefit. It then routes the PA request through the appropriate channel: medical benefit PAs via payer portals or X12 278 (often through a clearinghouse), and pharmacy benefit PAs via PBMs and ePA platforms, streamlining the process for both categories.